An interventional study of Mediterranean diet and Hypercaloric, hyperproteic oral nutritional supplement in Sarcopenia, sponsored by Maimónides Biomedical Research Institute of Córdoba. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-06.
Sponsored by Maimónides Biomedical Research Institute of Córdoba · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 99 studies in Sarcopenia with a site in Spain — 33 open to participants now, 40 under way, none of them phase 3. Sarcopenia · Spain.
Among the 99 studies in Sarcopenia with a site in Spain, this one is the 42nd largest by planned enrollment of the 77 interventional ones that give a count, is one of 14 that started in 2024, is one of 70 with no phase, reaches primary completion later than 20 of the 39 other live ones, and was the 54th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →33 of the 99 studies in Sarcopenia with a site in Spain are open now. Recruiting first, the newest first:
University of Valencia · Sites in Spain
Ages 18–99
Universidad de Granada · Sites in Spain
Ages 65+
University of Salamanca · Sites in Spain
Ages 18+
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal · Sites in Spain
Ages 80+
Sara Casanova Prieto · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
99 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 14 started in 2024.
This study's planned enrollment of 60 is close to the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 72 across the 77 interventional studies, 156 across the 22 observational. Of the 48 that completed or were terminated, 2 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 99 have an industry lead sponsor. The 10 most frequent:
Maimónides Biomedical Research Institute of Córdoba is the lead sponsor of 79 studies on the registry; 19 are open to participants now.
Maimónides Biomedical Research Institute of Córdoba has 4 studies filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
15 of the studies in Sarcopenia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07387770University of SalamancaMuscle Deterioration in Hospitalized Cancer Patient | 2026-11-30 |
| NCT07275996Universidad de BurgosNeuromuscular and Multi-Omics Synergy of Combined Creatine × HMB Supplementation Plus Exercise to Improve Muscle Function in Sarcopenic Frailty | 2026-12-30 |
| NCT06634316Maimónides Biomedical Research Institute of CórdobaSarcopenia in Patients With Heart Failure | 2026-12-31 |
| NCT07447375University of SalamancaExercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality | 2026-12-31 |
| NCT06015971Maimónides Biomedical Research Institute of CórdobaOmega-3 Fatty Acids and Nutritional Support in Gastrointestinal Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 99 studies in Sarcopenia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sarcopenia is a frequent complication in patients with cancer and chronic diseases, it is characterized by decreased muscle strength and fatigue due to reduced skeletal muscle mass, which is accompanied by atrophy and decreased quality of muscle tissue. In all cases, it negatively impacts treatment tolerance, clinical outcomes and survival, in consequence, quality of life of these patients decreases while morbidity, mortality and costs increase. In this context, appropriate nutritional screening and early nutrition support are extremely recommended, to this aim, in some cases, oral nutritional supplements (ONS) are necessary; ONS could have a standard formula or be enriched with specific nutrients. There is a lack of evidence for supporting its use or the use of protein modules in other clinical conditions including patients with heart failure
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mediterranean diet and physical exercise
Other: Mediterranean diet · Combination Product: Vitamin D supplementation · Combination Product: Physical exercise
Standard hypercaloric hyperproteic oral supplement plus Mediterranean diet and physical exercise
Other: Mediterranean diet · Dietary Supplement: Hypercaloric, hyperproteic oral nutritional supplement · Combination Product: Vitamin D supplementation · Combination Product: Physical exercise
Protein module (10g/day) plus Mediterranean diet and physical exercise
Other: Mediterranean diet · Dietary Supplement: Protein module · Combination Product: Vitamin D supplementation · Combination Product: Physical exercise
Mediterranean diet recommendations and daily physical exercise
Hypercaloric, hyperproteic oral supplement combined with Mediterranean diet recommendations (2 per day) and daily physical exercise
Protein module (10g/day) combined with Mediterranean diet recommendations and daily physical exercise
Calcifediol supplement administered orally in order to reach sufficiency levels (30 ng/ml)
Physical exercise adapted to patients with heart failure (Cardiac rehabilitation)
Muscle mass
Changes in muscle mass
Time frame: 6 months
Functionality
Changes in functionality determined by the up and go test
Time frame: 6 months
Albumin
Changes in serum albumin levels (g/dl)
Time frame: 6 months
C-RP
Changes in serum C-RP (g/dl)
Time frame: 6 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Dec 2026, 25 months after the start.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's planned 25 months is above that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maimónides Biomedical Research Institute of Córdoba